Ventiv wins Bayer work and promotes three

Share this article:
Ventiv Pharma Services promoted Brad Patten to vice president of marketing and corporate development. He was the executive director of managed markets and business development. Julia Kelly was promoted to executive director, marketing. Andy Baldwin was promoted to senior director of network services.
The group also signed an agreement with Bayer's Diabetes care division, in which Ventiv will deploy a team of sales representatives to promote Bayer's complete range of Ascensia diabetes care products and services to retail pharmacists, strengthening Ventiv's service offering in this product category.
Terrell Herring, president and chief operating officer of Ventiv Pharma Services, said, "We have worked with Bayer over the past several years, and are very pleased to be able to provide our services to another Bayer HealthCare division. This decision underscores Bayer's continued confidence in Ventiv's ability to deliver positive results with their diagnostic product line."
"Pharmacists play a pivotal role in the lives of people with diabetes, and often are a person's most local or most trusted source of health information," said David Argento, director, national accounts for Bayer HealthCare's Diabetes care division. "By teaming with Ventiv, Bayer believes it can achieve one of its primary goals of supporting these health professionals in a way that has a meaningful impact on the lives of their patients."
Share this article:

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.